title: Neuromodulators for migraine prevention.
abstract: Migraine is a debilitating condition characterized by a cycle of painful headaches and headache-related symptoms interspersed with periods of worry, distress, and apprehension. The negative impact of migraine on patient functioning, workplace productivity, and other daily activities has been demonstrated through the use of a variety of clinician- and patient-reported assessment tools, including the Migraine-Specific Questionnaire and the Migraine Disability Assessment questionnaire. In addition to considering the frequency and severity of migraine, clinicians need to encourage more open dialogue with their patients about the impact of this disorder on daily activities and productivity. Only then can the most appropriate course of treatment be determined. Appropriately prescribed acute and preventive therapies should break the cycle of migraine and improve the daily activities of patients with this chronic condition. Divalproex sodium and topiramate are neuromodulators that are approved by the US Food and Drug Administration (FDA) for the prophylaxis (prevention) of migraine headache in adults. Non-FDA-approved neuromodulators sometimes used in the management of migraine headache include gabapentin, lamotrigine, levetiracetam, and zonisamide. All medications need to be titrated, and treatment-related adverse events need to be managed appropriately. Preventive medications should be taken for at least 2-3 months to ascertain their therapeutic effect.
authors.affiliation: University of Pittsburgh Headache Center, Pittsburgh, PA 15213, USA.
authors.forename: Robert
authors.initials: R
authors.lastname: Kaniecki
mesh_terms: D006801:Humans; D008881:Migraine Disorders / Q000517:prevention & control*; D018377:Neurotransmitter Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D018377:Neurotransmitter Agents